Novel antibiotic and antitumor agent produced by the marine actinobacterium Streptomyces althioticus

OFFER from Spain, reference: TOES20190326002, valid from 26-03-2019 untill 04-10-2019

Technology
  • Title:
    Novel antibiotic and antitumor agent produced by the marine actinobacterium Streptomyces althioticus
  • Start date:
    26 maart 2019
  • End date:
    4 oktober 2019
  • Summary:
    A Spanish research group has patented a novel bacterial strain of Streptomyces althioticus, which is able to efficiently produce by fermentation cytotoxic compounds of the family of desertomycins. Specifically, this strain is producing a new desertomycin, having cytotoxic activity against different tumour cell lines and antibacterial activity against pathogenic bacteria. Companies in microbiology and pharmacy are sought to develop applications of the described invention under license agreements.
  • Description:
    Marine environments are emerging as a source of new natural products of pharmacological importance and intertidal macroalgae have revealed as a medium that should be investigated to discover structurally unique natural products with biomedical relevance. Due to the increasing need for new antitumor agents with improved activity, fewer undesirable side effects and greater selectivity compared to the current drugs in use in the fight against cancer and to the increasing emergence of current antibiotic-resistant pathogenic bacteria, it is necessary to develop new antitumor agents with improved pharmacological properties and of new antibiotics with potential biomedical treatment or prevention of infectious diseases caused by pathogenic bacteria. It is also necessary to have simple, short and economical methods for obtaining such compounds with antitumor and / or antibacterial activity.

    Researchers from a Spanish university working in microbiology provide a novel bacterial strain of Streptomyces althioticus that has been isolated from its natural environment, which is able to efficiently produce by fermentation compounds of the family of desertomycins. Specifically, this strain is producing a new desertomycin, which has cytotoxic activity against breast and colon tumour cell lines and also strong antibiotic activity against Mycobacterium tuberculosis and other clinically relevant pathogens.

    The present invention thus relates to a bacterial strain of Streptomyces althioticus, to a supernatant or extract of a culture of such bacterial strain, to the use of the bacterial strain for the production of certain desertomycin, to a process for obtaining said desertomycin, to a pharmaceutical or cosmetic composition, to the manufacture of a medicament for the treatment of cancer and for the treatment and / or prevention of bacterial infections or for removal and / or prevention and / or inhibition of bacterial biofilm formation, preferably on inert surfaces, i.e. ex vivo.

    The researchers would like to reach license agreements with companies operating in the clinical microbiology and pharmacy fields with the aim to develop applications of the described technology.
Partner Sought
  • Type of Partnership Considered:
    License agreement
  • Technical Specification or Expertise Sought:

    Type of partner sought: industry.
    Area of activity of the partner: companies working in clinical microbiology and pharmacy fields.
    Task to be performed: applications of the described technology.

    SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500

Organisation
  • Development stage:
    Under development/lab tested
  • IPR Status:
    Patent(s) applied for but not yet granted
  • Market keywords:
    Microbiology
    Oncology
    Pharmaceuticals/fine chemicals
    Marine products
  • Technology keywords:
    Cytology, Cancerology, Oncology
    Pharmaceutical Products / Drugs
    Virus, Virology/Antibiotics/Bacteriology
    Microbiology
  • NACE keywords:
  • Advantages and Innovations:
    The present invention represents a solution to the need for new antitumor compounds with biomedical potential in the treatment or prevention of infectious diseases caused by Gram positive and Gram negative pathogenic bacteria. It also represents a solution to the need for simple, short and economic procedures for obtaining said compounds with antitumor and antibacterial activity as the method of the invention allows to produce such compound by fermentation with an actinobacteria, rather than by chemical synthesis, which is a more complex, lengthy and costly process. In this regard, in biotechnological processes involving obtaining structurally complex natural products, such in the case of desertomycins, the production by fermentation using the producing microorganism is the preferred method because it is simpler, shorter and cheaper than the organic synthesis procedure.
Client
  • Type and Size of Organisation:
    University
  • Already Engaged in Trans-National Cooperation
    Ja
  • Year Established:
    0
  • Turnover:
  • Country of origin:
    Spain
  • Languages spoken
    • English
    • Spanish